Bladder Cancer | Tumor

Announcing BCAN’s 2021 Young Investigator Award

January 30th 2021, 12:30pm


The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).

BCAN Announces 2021 Bladder Cancer Research Innovation Award

January 26th 2021, 12:00pm


BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.

BCAN Ranked as a Top Charity with a 4-Star Ranking for Seventh Consecutive Year

January 18th 2021, 12:00pm


The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.

BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients

January 11th 2021, 2:00pm


The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

Higher Tumor Classification and Grade for Nonmuscle-Invasive Bladder Cancer May Increase Recurrence and Progression Risk Up to Five Years

December 1st 2020, 7:30pm


Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

Immunotherapy Just After Chemo May Allow Some Patients with Bladder Cancer to Maintain Health Benefits

September 30th 2020, 9:00pm


Patients with advanced or metastatic bladder cancer, after responding to initial treatment with chemotherapy, may preserve their health improvements by starting immunotherapy immediately.

There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment

September 30th 2020, 3:00pm


After treatment for bladder or prostate cancer, many survivors confront permanent sexual side effects. The good news is that treatments and psychological support are available.

FDA Approves Bavencio as Frontline Maintenance Therapy in Advanced Bladder Cancer

July 1st 2020, 3:39pm


The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.

Infigratinib Appears Active Across All Lines of Treatment in Patients With Advanced Bladder Cancer

June 16th 2020, 7:45pm


"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.

Cabometyx-Tecentriq Combination Produces 'Encouraging Clinical Activity' in Previously Treated Bladder Cancer

June 12th 2020, 5:00pm


At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.